CVS announcement of cost-effective benchmarks puts ICER in the spotlight


In an article for STAT, Ami Gopalan touches on CVS Health’s latest effort to nudge drug makers to reduce launch prices to a reasonable level. With an increase of payers use of value assessments such as ICER, manufacturers need to come to terms with a health care marketplace that increasingly ties access to competitive cost-effectiveness.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.